Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate01
jRCT2031230562Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of saruparib in prostate cancer (PCa) (2 arms), sponsored by AstraZeneca. Primary endpoint: Radiographic progression-free survival. Started Jan 2024; status: active, not recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031230562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230562.